Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.62 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 4/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14078280 | 0.91 | MAPK14 (0.66) | MAPK14HSPB1LCKMAP2K1CSF1R | |
| SCHEMBL5224749 | 0.82 | MAPK14 (0.53) | MAPK14HSPB1LCKMAP2K1CSF1R | |
| SCHEMBL5116783 | 0.82 | MAPK14 (0.58) | MAPK14HSPB1MAPK11KDR | |
| SCHEMBL5113564 | 0.82 | MAPK14 (0.61) | MAPK14LCKMAP2K1CSF1RMAPK11 | |
| SCHEMBL4701504 | 0.82 | MAPK14 (0.69) | MAPK14HSPB1 | |
| SCHEMBL4702778 | 0.80 | MAPK14 (0.66) | MAPK14HSPB1 | |
| SCHEMBL4856639 | 0.77 | MAPK14 (0.77) | MAPK14LCKCSF1RMAPK11HTR1D | |
| SCHEMBL4819651 | 0.77 | MAPK14 (0.74) | MAPK14HSPB1 | |
| SCHEMBL4865129 | 0.77 | MAPK14 (0.70) | MAPK14LCKMAP2K1CSF1RMAPK11 | |
| SCHEMBL4855098 | 0.77 | MAPK14 (0.77) | MAPK14LCKMAP2K1CSF1RMAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425555-B2 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1499600-B1 | HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089393-A1 | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 8/4885HSPB1 158/4885LCK 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.